TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12942852
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Lutéran tablets (control)
Study: 10397377
Drug: Sparfloxacin 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 400 mg
Study: 10397377
Drug: Sparfloxacin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 800 mg
Study: 10397377
Drug: Sparfloxacin 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 1200 mg
Study: 10397377
Drug: Sparfloxacin 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 1600 mg
Study: 8889461
Drug: Pantoprazole 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 120 mg
Study: 1996921
Drug: Arecoline hydrobromide
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline hydrobromide (1.0 mg)
Study: 1996921
Drug: Arecoline hydrobromide
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline hydrobromide (0.5 mg)
Study: 6508224
Drug: Anaesthesia without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia without volatile agent
Study: 29523557
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (including stent retriever thrombectomy, aspiration, and alternative methods)
Study: 23952739
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel applied twice a day after stitches removal
Study: 23952739
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream applied twice a day after stitches removal
Study: 22610181
Drug: Negative mean
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative mean daily fluid balance
Study: 15207898
Drug: Toremifene (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toremifene (40 mg per day)
Study: 15207898
Drug: Post-treatment (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (1 year after cessation of anti-estrogen)
Study: 11306202
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens at 0.625 mg/d plus trimonthly medroxyprogesterone acetate at 5 mg/d for 13 days (HRT)
Study: 10137793
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug coverage for new enrollees
Study: 10137793
Drug: High-cost drugs
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cost drugs
Study: 10137793
Drug: Low users
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low users of prescription drugs
Study: 25264047
Drug: Mekabu (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mekabu (70 g) with a white rice-based breakfast
Study: 21814218
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of D+EX
Study: 20819421
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture 0.76 g/day
Study: 20819421
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture 1.52 g/day
Study: 20819421
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid mixture 1.52 g/day coadministered with conjugated linoleic acid 1.6 g/day
Study: 18417744
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (50% dose increase at randomization)
Study: 12591556
Drug: Extruded formulated
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extruded formulated complementary diet from maize and cowpea (L(1)A(1))
Study: 12591556
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (L(2)N)
Study: 12711184
Drug: Oseltamivir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the stomach
Study: 12711184
Drug: Oseltamivir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the proximal small bowel
Study: 12711184
Drug: Oseltamivir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the distal small bowel
Study: 12711184
Drug: Oseltamivir administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir administered via Enterion capsule (150 mg) to the ascending colon
Study: 7835241
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor scintigraphy (SRS) for insulinoma
Study: 7835241
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor scintigraphy (SRS) for gastrinoma
Study: 307546
Drug: L-5-hydroxytryptophan plus
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan plus carbidopa
Study: 31589276
Drug: Usual access
Normalized name: sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Usual access to medicines (n = 391)
Study: 31589276
Drug: Free distribution
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free distribution of essential medicines
Study: 28432326
Drug: T stem
Normalized name: wheat stem rust extract
DrugBank: Puccinia graminis (DB10706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T stem cell memory (TSCM) cells identified by phenotypic markers of CD4+ T cells; subsets characterized by IL-2/IL-15 receptors and APOBEC3G anti-viral restriction factors; no specific dosage or duration mentioned.
Study: 28432326
Drug: Endogenous HSP70
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endogenous HSP70 activation of TSCM and innate immunity pathways; no specific dosage or duration mentioned.
Study: 8429321
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin treatment (IVIg) for 5 consecutive days
Study: 8429321
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin treatment (IVIg)
Study: 31808538
Drug: Systemic analgesics
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic analgesics (control group)
Study: 27393218
Drug: Caphosol mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caphosol mouthwash plus standard oral care
Study: 27393218
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care alone
Study: 25591439
Drug: Dialysate APR
Normalized name: PrameGel Reformulated Apr 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate APR (2.5% glucose-based peritoneal dialysis solution)
Study: 25591439
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution APR
Study: 25591439
Drug: Shock group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock group (conventional intravenous resuscitation)
Study: 23151341
Drug: Q-1000 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-1000 (1000 mg/d of quercetin, 250 mg/d of vitamin C and 10 mg/d of niacin)
Study: 23151341
Drug: Q-500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-500 (500 mg/d of quercetin, 125 mg/d of vitamin C and 5 mg/d of niacin)
Study: 18180897
Drug: Graded therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graded therapy featuring integrative traditional Chinese and Western medicine including 1.8 g of Xuefuda orally once per day, intravenous dripping of 250 mL of hemostasis mixture twice a day, 1.2 g of clindamycin per day for stage I; Kangyanling intra-articular injection for stage II-III; 25 mg of sodium hyaluronate for stage IV.
Study: 27921221
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg every 4 weeks
Study: 27770397
Drug: Intermittent androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent androgen deprivation therapy (ADT) for 6 months
Study: 27770397
Drug: Continuous androgen
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous androgen deprivation therapy (ADT) for 36 months
Study: 23701149
Drug: 200 mcg
Normalized name: CrM 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg vaginal misoprostol
Study: 23701149
Drug: 400 mcg
Normalized name: Biotin 400 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mcg vaginal misoprostol
Study: 11016021
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (LA) 320 mg
Study: 2939219
Drug: Ketanserin (K),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (K), 40 mg twice daily
Study: 2939219
Drug: Metoprolol (M),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (M), 100 mg twice daily
Study: 30027406
Drug: Hexanic extract
Normalized name: hexane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexanic extract of Serenoa repens (HESr) 320 mg/day
Study: 20684401
Drug: Various strategies
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various strategies to avoid physician's inertia and combat patient's non-compliance, including titration, rescue medications, and self-monitoring.
Study: 20684401
Drug: Pill count
Normalized name: Pill Counting Tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill count for compliance verification during the placebo run-in period.
Study: 17432675
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group treated with anti‐anxiety drugs
Study: 11305823
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion (0.5 - 2 microg x kg(‐1) x min(‐1))
Study: 11305823
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo infusion)
Study: 2894232
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg twice daily
Study: 30484837
Drug: Mineralocorticoid antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Mineralocorticoid antagonists
Study: 26200278
Drug: Cabazitaxel 25
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel 25 mg/m every 21 days
Study: 26200278
Drug: Topotecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan 1.5 mg/m on days 1-5 every 21 days
Study: 22610788
Drug: sGC-RT (sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: sGC-RT (sequential CRT with gemcitabine and cisplatin)
Study: 22610788
Drug: Con-RT (cisplatin-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Con-RT (cisplatin-based concurrent chemoradiotherapy plus adjuvant PF chemotherapy)
Study: 18212696
Drug: Milrinone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (0.5 microg/kg/min infusion)
Study: 17021320
Drug: AIC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIC vaccine
Study: 9085959
Drug: Tourniquet kept
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet kept inflated for 10 min after I.A. injection of morphine (5 mg in 25 mL saline)
Study: 9085959
Drug: Tourniquet deflated
Normalized name: panthenol
DrugBank: Panthenol (DB11204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tourniquet deflated immediately after I.A. injection of morphine (5 mg in 25 mL saline)
Study: 1492861
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) 1.5 mg/d
Study: 1492861
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) 3 mg/d
Study: 1492861
Drug: Dihydroergocristine (DHEC)
Normalized name: Dihydroergocristine
DrugBank: Dihydroergocristine (DB13345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergocristine (DHEC) 6 mg/d
Study: 4080903
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 ml of pure alcohol per kg body weight)
Study: 31208470
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure treatment once per week for 4 weeks and calcipotriol betamethasone ointment once daily for 4 weeks
Study: 31208470
Drug: Calcipotriol betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriol betamethasone ointment once daily for 4 weeks
Study: 23110952
Drug: Bromocriptine (Bc;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (Bc; 16 mg/heifer)
Study: 23110952
Drug: Acyline (Ac;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyline (Ac; 3 μg/kg)
Study: 20429818
Drug: Brimonidine/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine/timolol fixed combination (BrTFC) twice daily for 6 weeks
Study: 20429818
Drug: Dorzolamide/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide/timolol fixed combination (DTFC) twice daily for 6 weeks
Study: 18373654
Drug: Baclofen 10
Normalized name: baclofen 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen 10 mg four times per day
Study: 15661416
Drug: Endourethral macroplastique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endourethral macroplastique injection
Study: 12442916
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel (67 mg/m2/week)
Study: 12442916
Drug: Every 3
Normalized name: Eligard Every 3 Months 22.5 MG per 0.375 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every 3 weeks paclitaxel (72.7 mg/m2/week)
Study: 1777370
Drug: Enzyme-inducing anticonvulsants
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enzyme-inducing anticonvulsants (carbamazepine, phenobarbitone or phenytoin)
Study: 6094457
Drug: Cefotaxime (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (50 mg/kg/im route)
Study: 30321268
Drug: Fact Box
Normalized name: ALLERGENIC EXTRACT, BOX ELDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fact Box decision support tools on antibiotics for pneumonia and artificial hydration in advanced dementia (at 1‐month)
Study: 28889759
Drug: Nintedanib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib with add-on pirfenidone (titrated to 801 mg three times daily)
Study: 28889759
Drug: Nintedanib alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib alone (150 mg twice daily)
Study: 22109997
Drug: Oral rapamycin
Normalized name: kanamycin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rapamycin plus bare-metal stent (OR + BMS)
Study: 19395185
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy (RT) 10 Gy
Study: 19395185
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation Therapy (RT) 20 Gy
Study: 19395185
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with doxorubicin (three drugs)
Study: 19395185
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with dactinomycin and vincristine (two drugs)
Study: 3891710
Drug: amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 250 mg three times a day for seven days
Study: 3891710
Drug: trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim 200 mg twice a day for seven days
Study: 30861997
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber intake ≥35 g (n = 15)
Study: 18267042
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of sulphadoxine/pyrimethamine (25 mg/kg of sulphadoxine/1.25 mg/kg of pyrimethamine)
Study: 18267042
Drug: Amodiaquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg/kg/day x 3 days)
Study: 16285277
Drug: Ondansetron (8‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8‐12 mg orally per day)
Study: 8824473
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of cyclosporine
Study: 1575336
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol (0.08 mg/kg loading dose and 0.5 mg.kg‐1.h‐1 infusion)
Study: 1575336
Drug: Moderate-dose propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate-dose propofol (0.16 mg/kg loading dose and 1.0 mg.kg‐1.h‐1 infusion)
Study: 1575336
Drug: High-dose propofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose propofol (0.32 mg/kg loading dose and 2.0 mg.kg‐1.h‐1 infusion)
Study: 3914701
Drug: Piroxicam at
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piroxicam at 20 mg per day
Study: 3914701
Drug: Ibuprofen at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen at 2,400 mg per day
Study: 20633037
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 100 mg/day starting on day 1
Study: 20633037
Drug: Phenytoin (PHT)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin (PHT) 1,000 mg on day 1 followed by 300 mg/day maintenance
Study: 17127586
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (2 g x kg(‐1) body mass x day(‐1))
Study: 17127586
Drug: Whole-body low-magnitude
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body low-magnitude (3.5 g), low-frequency (30 Hz) mechanical vibration (WBV) for 10 min each day
Study: 17127586
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement (2 g x kg(‐1) body mass x day(‐1)) + WBV
Study: 11712935
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy of medical treatment and predischarge exercise tolerance testing (n = 1106)
Study: 11712935
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy for patients with cTnI levels of 0.1 ng/mL or more (n = 1087)
Study: 11712935
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy for patients with cTnI levels of less than 0.1 ng/mL
Study: 11712935
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive strategy for patients with low-level (0.1-0.4 ng/mL) cTnI elevation
Study: 9130895
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist and FSH
Study: 8221426
Drug: Acetaminophen half
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen half dose (162.5 mg per capsule, 2 capsules)
Study: 8221426
Drug: Acetaminophen full
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen full dose (325 mg per capsule, 2 capsules)
Study: 8221426
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 identical capsules)
Study: 3310451
Drug: Immunoglobulin therapy
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoglobulin therapy
Study: 25143169
Drug: Dezoxine 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezoxine 0.1 mg×kg(‐1) and dexmedetomidine 0.4 µg×kg(‐1)×h(‐1) until the end of the first ocular muscle correcting
Study: 10492055
Drug: Salmeterol dry
Normalized name: salmeterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol dry powder, 50 microg twice daily
Study: 10492055
Drug: Formoterol dry
Normalized name: aclidinium / formoterol Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol dry powder, 12 microg twice daily
Study: 8610621
Drug: Combination lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination lovastatin and probucol
Study: 2015146
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine (with adrenaline) 3 mg/kg body weight (Group A)
Study: 2015146
Drug: 0.5% plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% plain bupivacaine 3 mg/kg body weight (Group B)
Study: 6123635
Drug: Cereal-based electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal-based electrolyte solution (30 g rice powder per litre)
Study: 6123635
Drug: Standard sucrose‐electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sucrose‐electrolyte solution
Study: 10961474
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg acetylsalicylic acid (ASA)
Study: 3839446
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg ciramadol
Study: 3839446
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg ciramadol
Study: 3839446
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ciramadol